Melane Sampson, Author at BioTuesdays

Executive Moves

Roth adds John Boris to healthcare investment banking team

John Boris John Boris has joined Roth Capital Partners’ healthcare investment banking team as a managing director. Prior to joining Roth, Mr. Boris was the managing partner of JTB Capital Management, where he invested...

May 19, 2021

Developments

KA Imaging installs 2 mobile X-ray units at University Health Network

Closely-held KA Imaging installed two new mobile X-ray units in the University Health Network of Toronto to enhance current clinical studies and support patient care, with one unit is being used at the Princess Margaret...

May 18, 2021

Developments

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...

May 17, 2021

Developments

Arctic Vision in exclusive licensing pact with ActualEyes

Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...

May 14, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Markets

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

May 4, 2021

Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021

Author - Melane Sampson

Roth adds John Boris to healthcare investment banking team

KA Imaging installs 2 mobile X-ray units at University Health Network

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Arctic Vision in exclusive licensing pact with ActualEyes

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Ladenburg starts 4D Pharma at buy; PT $35

Clene presents positive Phase 2 interim ALS efficacy data

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

SVB Leerink starts VectivBio at OP; PT $28

Cantor starts Clene at OW; PT $22

Subscribe